Herlev

• The GranStone Trial Pending
  2026-525608-85-00 10 Paraffin Oil Induced Granulomatous Disease
• Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events Pending
  2026-525728-18-00 3 All CTCAE (v. 6.0) grade 2-4 immune-related adverse events
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting
  2025-524160-38-00 5 2026-05-12 Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad … Recruiting
  2024-518840-18-00 5 2025-12-10 Varicella
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• An RCT investigating hCG priming in women with diminished ovarian reserve Recruiting
  2025-521234-28-00 5 2025-09-10 Infertility, diminished ovarian reserve.
• Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) Recruiting
  2023-509703-33-00 6 2025-06-26 Septic Shock
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 6 2025-06-26 Acute critical illness requiring intensive care unit admission.
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 6 2025-05-26 Recurrent non-muscle invasive bladder cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting
  2023-503545-67-00 5 2024-04-30 Tourette's Disorder
• A phase I, multicentre, open-label, dose escalation study to determine the safety and preliminary efficacy of MBS8(1V270) administered intra … Recruiting
  2024-512294-26-00 1 2024-04-10 Advanced solid tumors
• Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag … Recruiting
  2022-501099-24-00 5 2023-12-22 Migraine
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting
  2022-501100-94-00 5 2023-11-08 Episodic Migraine
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone … Recruiting
  2024-513416-98-00 4 2023-01-23 Diabetes type 2
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic

Showing 25–48 of 293 trials